scispace - formally typeset
D

Dennis C. Dean

Researcher at Merck & Co.

Publications -  76
Citations -  5370

Dennis C. Dean is an academic researcher from Merck & Co.. The author has contributed to research in topics: Radioligand & Receptor. The author has an hindex of 27, co-authored 76 publications receiving 5169 citations. Previous affiliations of Dennis C. Dean include United States Military Academy.

Papers
More filters
Journal ArticleDOI

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1).

TL;DR: A binding assay is developed and shown that labeled ezetimibe glucuronide binds specifically to a single site in brush border membranes and to human embryonic kidney 293 cells expressing NPC1L1, which unequivocally establish NPC1 L1 as the direct target of ezETimibe and should facilitate efforts to identify the molecular mechanism of cholesterol transport.
Journal ArticleDOI

Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission.

TL;DR: The finding that metabolism of the TZD ring of troglitazone was catalyzed selectively by P450 3A enzymes is significant in light of the recent report that trog litazone is an inducer of this isoform in human hepatocytes.
Journal ArticleDOI

Identification of a new G-protein-linked receptor for growth hormone secretagogues

TL;DR: A specific high affinity binding site in porcine and rat anterior pituitary membranes that mediates the activity of these secretagogues has now been identified and is tightly correlated with GH-secretory activity.